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Abstract 
This review summarizes recent advances in our understanding of neuronal T-type calcium channel regulation as well as 
their physiological and pathophysiological roles. Through their ability to conduct calcium across the cellular membrane at potentials 
close to the resting potential, T-type calcium channels are critically important for regulating neuronal excitability, both in the central 
and peripheral nervous system.  T-type channels are also linked to an increasing number of neurological disorders such as the 
absence epilepsy and neuropathic pain.  Although there is substantial literature dealing with regulation of native T-type channels, the 
underlying molecular mechanism has only recently been addressed.  It is, therefore, critical to understand the cellular mechanisms 
that control T-type channel activity and expression, because this could provide important insight into designing novel therapeutic 
strategies targeting these channels.  
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Introduction 
Calcium is a ubiquitous intracellular second 
messenger critical for cellular functioning [1].  Voltage-
gated calcium channels are essential mediators of rapid 
influx of extracellular calcium ions into the cytosol of the 
electrically excitable cells.  The ensuing rise in free 
intracellular calcium levels triggers various responses, 
which include the activation of calcium dependent 
enzymes, the secretion of neurotransmitters and 
hormones, as well as proliferation, differentiation, 
apoptosis and cell death [1, 2].  Higher organisms express 
multiple calcium channel subtypes in various tissues [3-
27] (Table 1 and 2). 
The L-type calcium channels comprise the 
subgroup most studied, or high voltage-activated (HVA) 
calcium channels, which are well known, because they 
represent the main target of the antihypertensive drugs 
labelled “calcium channels blockers” [28].  Other 
members of the HVA channel family include the N-, P-, Q- 
and R-types. These channel subtypes are 
heteromultimers comprised of a pore forming α1 subunit 
that defines the calcium channel subtype, plus ancillary β, 
and α2-δ subunits which co-assemble with the α1 subunit 
to form a functional calcium channel protein [28] (Fig. 
1A).  All calcium channel α1 subunits are made of four 
homologous domains (I through IV), each of which 
containing 6 transmembrane spanning helices (termed 
S1-through S6) plus a pore forming loop, that permits the 
selective passage of calcium ions (Fig. 1B).  The S4 
segment in each domain contains positively charge amino 
acid residues in every third position (see “+” signs in Fig. 
1B) and forms the voltage sensor, which allows the 
channel to open and close in response to membrane 
potential changes.  The major transmembrane domains 
are linked by intra-cytoplasmatic loops. 
The N- and C-termini are also localized at the 
cytoplasmic sides.  In contrast, T-type calcium channels, 
or low voltage-activated (LVA) calcium channels, 
represented an electrophysiological curiosity at the time 
when they were first described because they differ from 
the members of the HVA family in three key areas.  First, 
they require much smaller membrane depolarization close 
to the resting membrane potential in most excitable cells 
for opening [2].  Second, their unitary conductance is 
typically smaller [2]. 
Finally, unlike HVA channels, it is thought that T-
type calcium channels are α1 subunit monomers [2].  Also 
in contrast with the L-type, these channels present rapid 
gating kinetics and resistance to standard calcium 
channel blockers. Journal of Medicine and Life Vol. 4, No. 2, April‐June 2011 
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Table 1: Voltage-dependent calcium channel family. The family, subfamily, old nomenclature, new nomenclature and type are 
indicated. 
HVA  Cav1  Cav1.1  α1S  L-type 
    Cav1.2  α1C  L-type 
    Cav1.3  α1D  L-type 
    Cav1.4  α1F  L-type 
         
  Cav2  Cav2.1  α1A  P/Q-type 
    Cav2.2  α1B  N-type 
    Cav2.3  α1E  R-type 
         
LVA  Cav3  Cav3.1  α1G  T-type 
    Cav3.2  α1H  T-type 
    Cav3.3  α1I  T-type 
 
Table 2: Tissue distribution of T-type calcium channel isoforms. 
Tissue  Location  Isoform  Method  Reference 
brain  ubiquitous  3.1,3.2,3.3  immunohistochemistry, in 
situ hybridization 
3, 4, 5 
peripheral 
nervous 
tissue 
DRG, autonomic ganglia, retina, olfaction  3.1,3.2, 3.3  electrophysiology   6, 7, 8, 9 
heart  myocytes (atrial, ventricular, septal) 
pacemaker cells (Purkinje cells, sinoatrial node cells, 
latent pacemaker cells) 
3.1, 3.2 
 
immunohistochemistry, 
mRNA, electrophysiology 
10, 11, 12, 
13, 14, 15 
smooth 
muscle 
vascular  3.1, 3.2  immunohistochemistry, 
mRNA, electrophysiology 
16 
  non-vascular: urinary tract (bladder, urethra, prostate), 
kidney (afferent and efferent arterioles, vasa recta, 
distal tubules, cortical collecting ducts), gastro-intestinal 
tract (stomach, small intestine, colon, spleen, liver), 
myometrium (uterus), male genitary tract (vas 
deferens),  airway 
3.1, 3.2 
 
immunohistochemistry, 
mRNA, electrophysiology 
17 
skeletal 
muscle 
embryonic, newborn   3.2  mRNA, electrophysiology  18, 19 
endothelium    3.1    20 
bone  osteoblasts  3.1    21 
endocrine  adrenal, pituitary, pancreas, thyroid, ovary  3.1, 3.2  immunohistochemistry, 
mRNA, electrophysiology 
22, 23, 24, 
25 
sperm    3.1, 3.2  immunohistochemistry, 
mRNA, electrophysiology 
26 
lung    3.1, 3.2  mRNA, electrophysiology  27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 General structure of the voltage-
dependent calcium channels. A. These 
channels are heteromultimers comprised of a 
pore forming α1 subunit plus ancillary β, and 
α2-δ subunits, which co-assemble with the α1 
subunit to form a functional calcium channel 
protein. B. Transmembrane topology of the T-
type calcium channel α1 subunit.   
 Journal of Medicine and Life Vol. 4, No. 2, April‐June 2011 
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Although these channels have been identified 
more than 25 years ago [6, 9, 10, 29, 30] it was not until 
later when the three cDNAs have been cloned, that the T-
type calcium channels began to be in the centre of 
attention.  In vertebrates, the T-type calcium channel 
family encompasses three different α1 subunit genes: 
CACNA1G, CACNA1H and CACAN1I, which encode α1G, 
α1H, and α1I, respectively (or as per current nomenclature, 
Cav3.1, Cav3.2 and Cav3.3, respectively) [11, 27, 31-33] 
with unique functional and pharmacological profiles, and 
specific cellular and subcellular distributions [2-5, 12, 17, 
34] (Table 1 and 2).   Also, the analysis of the cDNAs 
clearly indicate that many splice variants exist for the 
three Cav3.1, Cav3.2 and Cav3.3 subunits which 
enhances the diversity of T-type channels isoforms and 
there is growing evidence for significant differences in the 
electrophysiological properties of these splice variants of 
a given Cav subunit [35-39].    
This review focuses on the roles and 
regulation of neuronal T- type channels. Our goal, 
however, is not to present in detail all the roles and 
regulations of the T-current studied so far but to highlight 
some of the recent advances in our understating of T-type 
channel regulation and their functional roles in health and 
disease in the nervous system.  
 
Physiological and pathophysiological roles of T-type 
channels 
Neuronal T-type calcium channels were first 
identified in Purkinje and inferior olivary neurons and later 
in many other central neurons and in peripheral sensory 
neurons [6, 9, 10, 29, 30].  The role of T-type channels in 
regulating the neuronal firing patterns (low-threshold 
calcium spikes, action potential burst firing, post-
hyperpolarisation rebound action potentials and burst 
firing) is determined by the very interesting biophysical 
characteristics of these channels [reviewed in 40].  
Because T-type calcium channels are available for 
opening only from very negative membrane potentials 
they are ideally suited for regulating neuronal excitability 
[reviewed in 40 and 41] (Fig. 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 Key functional properties of T-type calcium channels. A. Simplified scheme of T-type channel gating. B. Typical family of 
whole cell T-type calcium currents, elicited by stepping from a holding potential of -110 mV to a series of incremental 
depolarizations. C. Voltage dependence of activation and inactivation.   The overlap of the activation and inactivation curves gives 
rise to a window current (i.e., a voltage range where T-type channels can be tonically active).  Journal of Medicine and Life Vol. 4, No. 2, April‐June 2011 
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Small membrane depolarisations can trigger the 
opening of T-type calcium channels and calcium entry, 
which in turn serves to further depolarise the plasma 
membrane, thus initiating action potentials bursts.  The T-
type currents are transient because the channels 
inactivate rapidly upon depolarization (Fig. 2B and C).  
However, when the membrane repolarises, T-type 
calcium channels deactivate slowly and this permits 
significant calcium influx following an action potential. 
Paradoxically, transient membrane hyperpolarisation can 
also augment T-type calcium channel mediated burst 
activity in a phenomenon termed “rebound bursting”. At 
normal neuronal resting membrane potentials, a large 
portion of T-type calcium channels is tonically inactivated 
[2, 7] (Fig. 2C).  Transient membrane hyperpolarizations 
(such as those arising from inhibitory postsynaptic 
potentials, or activation of certain types of potassium 
channels) results in recovery of these channels from 
inactivation, thus increasing the number of channels that 
are available for opening upon subsequent membrane 
depolarisations and enhancing their abilities to trigger 
action potential bursts.   
Another interesting feature of T-type channels is 
the pronounced overlap in the voltage ranges of activation 
and inactivation.  Thus a small fraction of the channels will 
remain tonically active at membrane potentials within this 
region of overlap (which is close to the resting membrane 
potential) leading to the generation of the so-called 
window current [42] (Fig. 2C).  This feature has been 
linked to the well-documented role of T-type calcium 
channels in neuronal activity [42].  The intrinsic window 
current provides a means for cardiac automaticity, 
although the precise mechanism by which these channels 
regulate the excitability of cardiac tissue remains a 
subject of debate [reviewed in 13], and also provides a 
means for T-type channel mediated calcium entry that 
triggers hormone secretion in the heart, kidney and 
neuroendocrine tissues [22, 23, 43].      
The well documented role of T-type calcium 
channels in regulating neuronal firing patterns occurs 
under normal physiological conditions, such as during 
sleep rhythms [44-47].  However, there is a growing body 
of evidence related to the roles of the T-type calcium 
channels under pathophysiological conditions such as 
epilepsy, autism, hypertension, atrial fibrillation, 
congenital heart failure, pain, psychoses and cancer [12, 
14-17, 20, 41, 43, 48-65].  It is well established that T-type 
calcium channels are critical players in the development 
of generalized seizures in humans and animals [55, 65].  
Knockout of Cav3.1 calcium channels protects mice from 
absence seizures [48, 57], and number of mutations have 
been described in Cav3.2 channels in patients with 
childhood absence and other forms of idiopathic 
generalized epilepsies [52, 55, 65]. However, when 
introduced into recombinant channels that are functionally 
expressed in heterologous systems, the functional 
consequences of the majority of the known Cav3.2 
epilepsy mutations are subtle, and in some cases not 
detectable [52, 54, 56, 64].     
Increased T-type channel activity has also been 
linked to neuropathic and inflammatory pain states [60].  
Inhibitors of T-type calcium channels mediate analgesia 
when injected intrathecally into rats. Selective in vivo 
antisense knockdown of Cav3.2 channel antagonizes 
neuropathic and inflammatory pain [49, 51] whereas 
knockdown of the Cav3.2 and Cav3.3 reverses tactile 
allodynia and thermal hyperalgesia in rats [50].  
Conversely, T-type calcium channel activity is upregulated 
during diabetic neuropathy [53]. This is consistent with T-
type calcium channels playing a major role in regulating 
the excitability of primary afferent pain fibers.  
Recently, there has been new evidence that T-
type calcium channels may be involved in other 
pathophysiological processes. Splawski et al. [58] 
described several missense mutations within CACNA1H 
gene linked to autism spectrum disorder.  These 
mutations were responsible for significantly altering the 
Cav3.2 channel activity by causing a positive shift in the 
activation properties and a reduction in conductance.   
Interestingly a third of the autism spectrum disorder 
patients suffer from epilepsy [58]. Although autism is a 
complex developmental disorder it is tempting to 
speculate based on the role of T-type calcium channels in 
the neuronal development and excitability [66] that 
mutations in the CACNA1H gene may affect the neuronal 
function during neurogenesis [67] and could play a critical 
role in the development of autism. Another recent study 
explored the effects of a novel selective T-type calcium 
channel inhibitor, which produced antipsychotic-like 
activity [61]. This compound blocked the psychostimulant 
effects of amphetamine and MK-801 by decreasing the 
amphetamine-induced c-fos expression as well as MK-
801-induced glutamate levels in the nucleus accumbens.  
Basal, amphetamine- and MK-801-induced dopamine 
efflux was altered. These findings suggest that T-type 
calcium channel selective blockers could represent a 
novel treatment for schizophrenia. T-type calcium channel 
antagonists could be a viable treatment for essential 
tremor as demonstrated by Handforth and colleagues [62] 
in two mouse models.  These findings suggest a role for 
T-type calcium channels, especially for Cav3.1, which is 
the dominant subtype expressed in the inferior olive, in 
essential tremor.  Not only theT-type calcium channels 
may play a role in essential tremor but also they appear 
as viable targets in the treatment of parkinsonian tremor 
[63]. 
It is clear that T-type calcium channels display 
unique functional properties that support a number of 
critical cellular functions in a variety of tissues, and their 
dysfunction is linked to neurological consequences.   
Furthermore, different cellular mechanisms are in place to 
fine tune T-type channel activity.   It is clear that T-type 
channels constitute important targets for clinically active 
drugs [43, 68-71].   Journal of Medicine and Life Vol. 4, No. 2, April‐June 2011 
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Physiological regulation of T-type channel function 
There is an extensive body of evidence 
regarding the regulation of T-type currents in response to 
activation of a range of G protein coupled receptors, such 
as angiotensin, GABAB, muscarinic (M1), corticotropin 
releasing factor receptor 1 (CRFR1) and serotonin 
receptors which in turn activate a wide range of 
intracellular second messenger pathways [8, 72-79] (Fig. 
3).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A number of serine/threonine kinases, 
calmodulin-dependent protein kinases and tyrosine 
kinases have been found to be involved in the regulation 
of T-type calcium channel.  One of the first to be 
described was CamKII [78], which was reported to have a 
selective potentiation effect on recombinant Cav3.2 
currents.  The authors showed that this effect is due to a 
hyperpolarizing shift in the activation curve of the channel, 
which in turn increases the size of the window current and 
makes the channel more available for opening. The 
domain II-III linker region of the channel was the key 
structural motif involved in CamKII regulation (Fig. 3), and 
subsequently Serine 1198 was identified as the key 
CamKII phosphorylation site involved in this effect [79].  It 
was also shown that Cav3.2 inhibition (but not other T-
type calcium channel subtypes) by direct interactions of G 
protein β2 and γ subunits (Gβ2γ) with the domain II-III 
linker region (Fig. 3) of the channel [80] and reduces the 
open probability of the channel [81].   
Fig. 3: Regulation of T-type channel activity by activation of G protein-coupled receptors and subsequently second messengers, 
redox factors, cations and novel modulators.  Note that the final coupling mechanism between these Gβγ subunits and the T-type 
channel is not understood.  Plus and minus symbols indicate the stimulation and inhibition of T-type channel activity, respectively. 
(GPCR – G protein-coupled receptors; PKG- protein kinase G, PKA – protein kinase A, PKC – protein kinase C, TK – tyrosine 
kinase, MAPKII – mitogen-associated protein kinase II, L-cys – L-cysteine; L-Ncys – L-nitrosocysteine; KLHL-1 – neuronal actin-
binding protein Kelch-like 1) Journal of Medicine and Life Vol. 4, No. 2, April‐June 2011 
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Protein kinase C activation reportedly enhances 
the activities of Cav3.1, Cav3.2 and Cav3.3 calcium 
channels [82] with the magnitude of upregulation being 
dependent on Cav3 channel subtype. The PKC effect 
could be localized also to the domain II-III linker region of 
the channel (Fig. 3), but the exact location of the PKC site 
within this region remains undefined.  Given that the 
CamKII effect occurred selectively for Cav3.2 and did not 
involve a change in the channel’s activation behaviour, it 
is likely that the PKC acts at a distinct site from that 
phosphorylated by CamKII.  Activation of protein kinase A 
(PKA) also upregulates Cav3.2 channel activity in 
Xenopus oocytes (Cav3.1 and Cav3.3 were not examined 
in this study [83] and the domain II-III linker region was 
again the critical determinant of this effect.  However, the 
authors could not identify the key PKA site involved in the 
PKA-mediated upregulation.  Interestingly, in mammalian 
cells, both PKA and PKC were reported to potently 
enhance all Cav3 channel subtype, but curiously, only at 
near physiological temperatures, whereas no modulation 
could be observed at room temperature [84].  It is unclear 
why PKC and PKA are able to enhance T-type channel 
activity at room temperature in oocytes and not in 
mammalian cells. It is important to note that T-type 
channel function is highly dependent on temperature [85], 
which may also affect their overall susceptibility to kinase 
regulation. 
Application of lysophospatidic acid (LPA) through 
activation of Rho kinase mediates a reversible inhibition of 
transiently expressed Cav3.1 and Cav3.3 calcium 
channels and a shift towards more depolarized potentials 
of the activation and inactivation curves for the Cav3.2 
channels  [86]. The site of action of Rho kinase could be 
localized to two clusters of serines and threonines within 
the domain II-III linker region of Cav3.1 (Fig. 3) that is 
highly conserved across all T-type calcium channel 
isoforms [86].  It has been shown that LPA can induce a 
reduction of rebound burst activity in lateral habenula 
neurons that rely on Cav3.1 channels for burst activity.  
Cav3.1 channels are widely distributed in the central 
nervous system and especially in the thalamus and 
neocortex [5] two of the areas known to be important for 
seizure genesis.  Recently it has been shown that ROCK 
inhibitors mediated a reduction of seizures in mice [87] 
pointing to a possible role for the Rho/Rho-kinase 
signalling pathway in epilepsy. Along these lines, LPA 
receptor activation has been linked to neuropathic pain 
[88], and it remains to be determined if this is due to 
altered Cav3.2 channel function.   
Overall, it is remarkable that a number of 
different second messengers act on T-type calcium 
channels via the domain II-III linker region. This suggests 
that this region is a key element involved in the regulation 
of T-type channel function. This also may provide a 
means by which clinically relevant T-type calcium channel 
mutations in this region could mediate neurophysiological 
effects without directly affecting the biophysical properties 
of the channels.   
T-type calcium channels can also be regulated 
by pathways that do not involve classical intracellular 
messengers (Fig. 3). Reducing agents such as the 
endogenous amino acid L-cysteine have been shown to 
upregulate T-type currents in nociceptive neurons, thus 
triggering the development of hyperalgesia [88] due to an 
increase in excitability of these neurons [90].   This type of 
redox modulation was shown to occur selectively for 
Cav3.2 channels, and could also be demonstrated in 
reticular thalamic neurons [90]. Conversely, oxidizing 
agents inhibited Cav3.2 calcium channels [91]. Moreover, 
T-type calcium channel inhibition and inhibition of burst 
firing of reticular thalamic was also observed upon 
extracellular, application of a series of endogenous s-
nitrosothiol reagents  such s L-nitrosocysteine [92], and 
by oxidizing agents such as ascorbate [93].  In the case of 
ascorbate, the mechanism of action was shown to involve 
an oxidization of a unique histidine residue (His191) in the 
domain I S3-S4 region of the Cav3.2 channel (Fig. 3).   
Interestingly, the same histidine residue was shown to be 
involved in the augmentation of Cav3.2 currents in 
response to L-cysteine but also in inhibition of the of the 
Cav3.2 currents in response to nitrous oxide (N2O). L-
cysteine was shown to chelate endogenous zinc ions that 
normally inhibit Cav3.2 channel activity thus relieving this 
inhibition and increasing current activity [94]. Nitrous 
oxide on the other hand is believed to be involved in the 
production of reactive oxygen species, which in turn are 
likely to oxidize H191 of CaV3.2 in a localized metal-
catalyzed oxidation reaction [95]. It should also be noted 
that in addition to the potent zinc mediated inhibition of 
Cav3.2 channels (IC50 ~800 nM), zinc ions cause an ~ 
100 fold slowing of Cav3.3 tail currents which culminates 
in increased Cav3.3 channel during action potential bursts 
[96]. These observations are particularly interesting when 
considering recent findings showing that the chelation of 
zinc ions can alter the occurrence and frequency of 
epileptiform discharges [97]. The authors suggested that 
this was the result of zinc-mediated modification of the 
gating kinetics of the Cav3.3 channel, a T-type channel 
isoform, highly expressed in the thalamic neurons [5]. 
Recently, the lead ion was shown to have an 
excitatory effect on T-type calcium channel activity and 
thereby on action potential firing of pyramidal neurons in 
CA1 region of the rat hippocampal slices [98]. This effect 
was very much different from that of zinc in that it 
appeared to involve the release of calcium from the 
internal stores through the inositol trisphosphate and 
ryanodine receptors. 
Endogenous modulators derived from amino 
acids appear to be key regulators of T-type channel 
function with actions that are inextricably linked to zinc 
inhibition of these channels.  The findings obtained with 
redox and oxidizing agents also serve to further Journal of Medicine and Life Vol. 4, No. 2, April‐June 2011 
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underscore the role of Cav3.2 T-type channel activity in 
pathophysiological states such as pain and epilepsy.  
Hildebrandt et al. have recently shown that 
activation of M1 muscarinic acetylcholine receptors 
selectively inhibits Cav3.3 channel activity [74]. The 
authors showed that this inhibition was mediated by Gαq 
/Gα11 linked pathways and partially involved Gβγ 
subunits. The M1 mediated modulation did not involve 
any of the major second messenger pathways, such as 
PKC, PKA, tyrosine kinases, PI3 kinases or calmodulin 
dependent protein kinase, or PIP2. Alltogether, this 
suggests a novel pathway for T-type channel regulation 
that needs to be explored further.  One possibility is a 
redundant inhibitory mechanism that in which two 
separate pathways are activated by M1 receptors 
concomitantly and each being capable of inhibiting 
channel activity.   Such a mechanism would be consistent 
with the authors’ observation that multiple channel regions 
appeared to be involved [74].  
Another recent study described a regulation of 
Cav3.2 channels by corticotrophin releasing factor (CRF) 
receptors [76].  The authors showed that activation of co-
expressed CRF1 receptors in HEK293T cells selectively 
inhibited Cav3.2 calcium channels. The inhibition was 
dependent on Gβγ subunits activated by a cholera toxin 
sensitive Gα pathway. However, the observed modulation 
differed from the aforementioned inhibition mediated by 
Gβ2γ in that a leftward shift in the half inactivation 
potential was observed.  Such a shift in the steady-state 
inactivation curve will lead to a decrease in size of the 
window current and therefore a reduced T-type channel 
availability for opening. This suggests that the CRF1 
receptor mediated regulation of Cav3.2 channels is 
unique. Agonists of the CRF receptors have been 
implicated in regulating sleep rythms [99]. Considering the 
well established role of the T-type channel in thalamic 
oscillations it is tempting to speculate that the observed 
effect of the CRF receptor activation on T-type channel 
gating may play a role in the regulation of sleep rhythms.  
A recent report by Kim and colleagues [100] showed that 
CRF receptor activation of T-type channels expressed in 
MN9D cells (a cell line with characteristics of 
dopaminergic neurons) results in inhibition of T-type 
channels that is dependent on PKC activity. This suggests 
that not only may the coupling between CRF receptors 
and T-type channel differ depending on the cellular 
environment, but also that effects of PKC activation may 
be highly dependent on cell type (recall the PKC mediated 
enhancement of T-type channels described above). It is 
possible that CRF receptor activation will produce 
different results depending on the T-type channel splice 
isoform. 
Aromoralaran et al. [101] that the neuronal actin-
binding protein (ABP) Kelch-like 1 (KLHL1) selectively 
increases Cav3.2 current density and deactivation 
kinetics. These changes lead to an overall increase in the 
calcium influx, through these channels, without a change 
in conductance or open probability. KLHL1 is a 
constitutive protein, which is widespread in the brain and 
contributes to the modulation of pacemaker activities, 
short burst firing, and low-threshold calcium spikes [67].  
KLHL1 also participates in neurite outgrowth and its 
genetic elimination in Purkinje neurons leads to dendritic 
atrophy and motor insufficiency. This is another novel 
regulatory mechanism and due to the large distribution of 
KLHL1 and T-type channel in the brain, it would be 
interesting to assess its contribution in pathophysiological 
instances.  
In spite of the many new insights into the T-type 
channel regulation gained in the last years our current 
understanding of the precise underlying molecular 
mechanisms remains relatively limited, and the putative 
vast majority of the pathways regulating native channels 
have not yet been reconstituted in heterologous 
expression systems.   
 
Regulation of T-type channel expression 
The subcellular distribution of T-type calcium 
channels across the central nervous system varies with T-
type calcium channel subtype and brain region [3, 5]. For 
example, in neocortical pyramidal cells, Cav3.1 channels 
show a mainly somatic distribution, whereas Cav3.3 
channels are expressed at both the soma, as well as the 
proximal and distal dendritic trees [3].  The molecular 
mechanisms that underlie the differential subcellular 
distribution of individual calcium channel subtypes are at 
this point unknown, as are the cellular mechanisms that 
regulate the trafficking of T-type calcium channels to the 
plasma membrane.  Co-expression of Cav3.1 calcium 
channel α1 subunit with HVA calcium channel β and α2-δ 
subunits increases α1 subunit surface expression levels 
[102, 103] and recently Bae and colleagues [104] showed 
a weak association between Cav3.3 calcium channel α1 
subunit and the β subunit. However, no physical 
association among these subunits has ever been 
demonstrated in vivo.  It is very possible that the different 
types of T-type channel are able to associate with 
different interacting proteins, which in turn may well affect 
the extent of membrane trafficking, and the specific 
targeting to appropriate subcellular loci.   
It has been shown that increased Cav3.2 
channel membrane expression occurs for channels 
carrying a number of different childhood absence epilepsy 
mutations [105].  It is unclear, however, whether this is 
due to altered ER retention, or due to increased 
membrane stability. There is also evidence for an 
increase in the T-type channel expression, in CA1 
pyramidal neurons in a rat model of temporal lobe 
epilepsy [106]. Direct effects of these epilepsy mutations 
on membrane expression or effects on interactions with 
regulatory proteins that are involved in channel targeting 
could potentially account for their pathophysiological Journal of Medicine and Life Vol. 4, No. 2, April‐June 2011 
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impact even in the absence of any alterations in channel 
biophysics. Another mechanism for a change in surface 
expression of T-type calcium channels could be mediated 
by the various hormonal changes that occur in epilepsy 
patients [107]. It has been shown that 17β-estradiol 
treatment induces an increase in the mRNA expression, 
which leads to increased functional expression of Cav3.1 
and increased burst firing in hypothalamic neurons in a 
guinea pig model [108]. It is possible that such a 
mechanism could underlie the increased T-type calcium 
channel expression that is observed in mouse models of 
absence epilepsy [57]. While potentially contributing to 
pathophysiology, altered regulating of either the extent of 
trafficking of the channels to the plasma membrane, or 
their stability in the plasma membrane may perhaps 
provide novel means of modulating T-type calcium 
channel activity for therapeutic purposes. 
An upregulation in T-type calcium channel 
expression also appears in painful diabetic neuropathy in 
dorsal DRG sensory neurons [53]. Conversely, 
knockdown of Cav3.2 and Cav3.3 localized to the spinal 
cord in rats mediates potent analgesia [49, 50].  
Therefore, it is tempting to speculate that blocking the 
trafficking of these channels to the cellular membrane 
could decrease or even completely abolish neuropathic 
pain. 
Channel expression can be regulated by 
alternate splicing events [36-39]. Alternate splice isoforms 
of each Cav3 channel subtype have been reported, and 
were shown to give rise to channels with distinct 
functional properties [36-39]. The distribution of specific 
splice variants across the brain and other tissues, and 
whether any such expression patterns may vary, the 
developmental state remaining yet to be described. A 
recent study has provided intriguing evidence that a 
number of childhood absence epilepsy mutations may 
affect the mRNA splicing of the Cav3.2 calcium channel 
gene, by eliminating splice junctions [38]. This in turn may 
give rise to inappropriate splice variants in specific 
tissues, which may then result in altered neuronal function 
[38]. Along these lines, when conducting mutagenesis 
studies, it is essential that the mutations are introduced 
into the appropriate splice variant, as effects of such 
mutations may manifest only in certain channel variants. 
Overall, although our understanding of the 
molecular mechanisms that regulate T-type channel 
expression at to mRNA and protein levels remain poorly 
understood. Alterations in the normal T-type channel 
expression patterns may well play significant roles in T-
type channel pathophysiology and a clear possibility 
emerges that T-type calcium channels can be good 
targets for controlling pain and absence seizures by using 
a genetic approach.    
Concluding remarks 
T-type calcium channels are critical contributors 
to membrane excitability in both neuronal and non-
neuronal cells, and conversely, aberrant T-type calcium 
channel function has been linked to a number of different 
disorders.  Although there is now an increasing 
understanding of the molecular determinants that underlie 
regulation of T-type channels by a range of second 
messenger pathways, the intricate mechanisms that 
control, T-type channel expression and distribution remain 
largely unknown. Today with the help of Cav3.1 and 
Cav3.2 knock out animals, we will be able to further 
explore the involvement of T-type calcium channels in 
physiological and pathophysiological states. The Cav3.1 
knock out mouse already helped to further our 
understanding of the major role of T-type calcium 
channels in sleep and absence epilepsy by regulating the 
neuronal burst firing in the thalamocortical relay neurons 
[44, 45, 48] while the Cav3.2−/− mice confirmed the role 
of the Cav3.2 in nociception [51]. Unfortunately, no report 
has been published yet to show the functional 
consequences of Cav3.3 knock-out. 
The effects of the changes in T-type channel 
activity could also be related to changes in potassium 
channel activity. Small- and large-conductance calcium-
activated potassium channels (SKCa and BKCa) have been 
shown to be functionally coupled in neurons and vascular 
smooth muscle cells were they are involved in regulating 
neuronal firing patterns and vasodilation, respectively 
[109-112]. Recently, voltage-activated potassium 
channels (Kv) have also been found to be coupled not 
only functionally but also physically to the T-type calcium 
channels [113, 114].   
The search for selective or subtype-specific 
blockers for T-type channels has been going on for years.  
However, these compounds are not yet available.  Many 
T-type channel blockers have been described in the 
treatment of neurological and cardiovascular disorders.   
These compounds belong to various drug classes 
(dihydropyridines, succinimide derivatives, 
diphenylbutylpiperidine derivatives, bendodiazepines, 
anesthetics) but their action is not selective enough for 
the T-type channel [68-71]. The search for new 
generations of selective T-type channel blockers is 
ongoing [43, 70, 71]. Due to the fact that T-type calcium 
channels have isoform-specific properties, the need to 
design drugs selective for a given T-channel subtype has 
emerged. The challenge will then be to determine whether 
specific T-channel isoforms/variants can be selectively 
targeted for therapeutic intervention. Although a new Journal of Medicine and Life Vol. 4, No. 2, April‐June 2011 
  134  © 2011, Carol Davila University Foundation
route has been started recently, with the utilization of 
genetic approaches, such as gene knockout by gene 
targeting or gene knockdown by antisense techniques 
[44, 48-50, 57], it does not represent a viable therapeutic 
approach at this time.  Understanding the regulatory 
mechanisms of the T-type calcium channel regulation and 
expression may lead to the identification of novel means 
of regulating T-type channel activity for therapeutic 
purposes, especially for controlling pain and absence 
seizures, thus underscoring the importance of closing 
these gaps in our current knowledge.  
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